https://www.gibf-bio.com/en/node/243
BioVersys and Partners' Phase 2a Tuberculosis Trial Results Published in New England Journal of...
https://biotech-365.com/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator-associated-bacterial-pneumonia-vabp-and-provides-a-business-update-2/
Bioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator...
patient visit
https://beam-alliance.eu/bioversys-announces-first-patient-first-visit-in-habp-vabp-pivotal-phase-3-riv-target-trial-of-bv100/
BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of...
Apr 16, 2026 - Achieving first patient first visit in the RIV-TARGET trial marks a significant milestone for BioVersys in the development of BV100 and more importantly for...
https://rx.news/bioversys-reports-strong-h1-2025-progress-in-antibacterial-drug-development/
BioVersys Reports Strong H1 2025 Progress in Antibacterial Drug Development
Sep 10, 2025 - These developments underscore BioVersys's ongoing commitment to addressing the critical global challenge of multi-drug resistant bacterial infections th...
reportsstrongprogressantibacterialdrug